Sonia Caraballo-Cartagena, MD
Neurology · Schaumburg, ILNPI 1184025132
Payments from drug & device makers
Across 495 payments — averaging $553.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$121K
- AstraZeneca$47K
- Argenx US, Inc.$25K
- Alnylam Pharmaceuticals Inc.$24K
- Johnson & Johnson$22K
- Takeda Pharmaceuticals U.S.A., Inc.$20K
- plus $16K from 27 others
What the payments were for
- Consulting fees$41,91215%
- Speaking & faculty fees$189,52069%
- Travel & lodging$30,14411%
- Food & beverage$12,1064%
- Education$1170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 195 | $120,594 |
| AstraZeneca | 71 | $46,689 |
| Argenx US, Inc. | 45 | $25,481 |
| Alnylam Pharmaceuticals Inc. | 29 | $23,524 |
| Johnson & Johnson | 27 | $21,778 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $19,977 |
| Amgen(2 entities) | 9 | $11,962 |
| Teva Pharmaceuticals USA, Inc. | 8 | $485 |
| AbbVie(2 entities) | 21 | $423 |
| Novartis | 13 | $409 |
| Banner Life Sciences, LLC | 3 | $339 |
| Genentech USA, Inc. | 6 | $322 |
| Biogen | 6 | $287 |
| Sanofi | 7 | $260 |
| EMD Serono, Inc. | 3 | $210 |
| Tanabe Pharma America, Inc. | 5 | $207 |
| Akcea Therapeutics, Inc. | 1 | $125 |
| Amneal Pharmaceuticals LLC | 1 | $120 |
| Biohaven Pharmaceuticals, Inc. | 1 | $115 |
| Lilly USA, LLC | 2 | $90 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $53 |
| CSL Behring | 2 | $53 |
| PTC Therapeutics, Inc. | 2 | $51 |
| Pfizer | 2 | $44 |
| TG Therapeutics, Inc. | 1 | $35 |
| Livanova USA, Inc. | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Acorda Therapeutics, Inc | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$273,798 in reported general payments places this provider in the 90th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KeveyisDichlorphenamide | 12 | $539,720 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $147,320 |
| BafiertamMonomethyl Fumarate | 14 | $93,779 |
| Nurtec OdtRimegepant Sulfate | 26 | $36,012 |
| Aimovig AutoinjectorErenumab-Aooe | 36 | $30,535 |
| UbrelvyUbrogepant | 17 | $18,492 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 73 | $1,632 |
| Pyridostigmine Bromide | 20 | $1,246 |
| Levetiracetam | 56 | $1,186 |
| Oxcarbazepine | 13 | $1,071 |
| Pregabalin | 14 | $773 |
| Memantine Hcl | 21 | $713 |
| Gabapentin | 117 | $656 |
| Propranolol Hcl | 40 | $601 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 36 | $548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Xeris Pharmaceuticals, Inc.Keveyis | $19 | $539,72012 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $19,977 | $147,32013 claims |
| PfizerNurtec Odt | $44 | $36,01226 claims |
| AbbVieUbrelvy | $423 | $18,49217 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $120 | $1,24620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 790 neurology providers in Illinois.
Other neurology in Schaumburg
- Daniel WynnNorthbrook$13.9M
- Concetta ForchettiElk Grove Village$8.5M
- Tatyana SimuniChicago$3.5M
- Danny BegaChicago$2.8M
- Thomas AlaSpringfield$2.4M
- Augusto MiravalleChicago$2.1M
- Leonard Verhagen MetmanChicago$1.8M
- Anthony RederBurr Ridge$1.6M
- Dusan StefoskiChicago$1.5M
- Kourosh RezaniaChicago$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.